Ethanol extract of Cyathulae Radix inhibits osteoclast differentiation and bone loss

Abstract

Cyathulae Radix, a traditional Chinese medicine and a common vegetable, boasts a history spanning millennia. It enhances bone density, boosts metabolism, and effectively alleviates osteoporosis-induced pain. Despite its historical use, the molecular mechanisms behind Cyathulae Radix’s impact on osteoporosis remain unexplored. In this study, we investigated the effects and mechanisms of Cyathulae Radix ethanol extract (CEE) in inhibiting osteoporosis and osteoclastogenesis. Eight-week-old female mice underwent ovariectomy and were treated with CEE for eight weeks. Micro-computed tomography (micro-CT) assessed histomorphometric parameters, bone tissue staining observed distal femur histomorphology, and three-point bending tests evaluated tibia mechanical properties. Enzyme-linked immunosorbent assay (ELISA) measured serum estradiol (E₂), receptor activator for nuclear factor B ligand (RANKL), and osteoprotegerin (OPG) levels. Osteoclastogenesis-related markers were analyzed via Western blotting (WB) and quantitative real-time polymerase chain reaction (qRT-PCR). Additionally, CEE effects on RANKL-induced osteoclast formation and bone resorption were investigated in vitro using tartrate-resistant acid phosphatase (TRAP) staining, qRT-PCR, and WB assay. Compared with the ovariectomy (OVX) group, CEE treatment enhanced trabecular bone density, maximal load-bearing capacity, and various histomorphometric parameters. Serum E₂ and OPG levels significantly increased, while Receptor activator of nuclear factor-κB (RANK) decreased in the CEE group. CEE downregulated matrix metallopeptidase 9 (MMP-9), Cathepsin K (CTSK), and TRAP gene and protein expression. In bone marrow macrophages (BMMs), CEE reduced mature osteoclasts, bone resorption pit areas, and MMP-9, CTSK, and TRAP expression during osteoclast differentiation. Compared with DMSO treatment, CEE markedly inhibited RANK, TNF receptor associated factor 6 (TRAF6), Proto-oncogene c-Fos (c-Fos), Nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) expressions, and Extracellular regulated protein kinases (ERK), c-Jun N-terminal kinase (JNK), NF-kappa B-p65 (p65) phosphorylation in osteoclasts. In conclusion, CEE significantly inhibits OVX-induced osteoporosis and RANKL-induced osteoclastogenesis, potentially through modulating the Estrogen Receptor (ER)/RANK/NFATc1 signaling pathway.

Keywords

Osteoporosis / Osteoclast / BMMs / Cyathulae Radix / RANKL / ER/RANK/NFATc1 signaling pathway

References

[1] Zhi X, Chen X, Su J. Advances in research on the mechanism of postmenopausal osteoporosis[J]. Chin J Osteoporos, 2018, 24(11): 1510-1513, 1534.

[2] Chinese Society of Bone and Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017)[J]. Chin J Osteoporos Bone Miner Res, 2017, 10(5): 413-443.

[3] Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling[J]. Arch Biochem Biophys, 2008, 473(2): 139-146.

[4] De Vries TJ, Schoenmaker T, Aerts D, et al. M-CSF priming of osteoclast precursors can cause osteoclastogenesis-insensitivity, which can be prevented and overcome on bone[J]. J Cell Physiol, 2015, 230(1): 210-225.

[5] Bourette RP, Rohrschneider LR. Early events in M-CSF receptor signaling[J]. Growth Factors, 2000, 17(3): 155-166.

[6] Kim HJ, Kang WY, Seong SJ, et al. Follistatin-like 1 promotes osteoclast formation via RANKL-mediated NF-Kappa B activation and M-CSF-induced precursor proliferation[J]. Cell Signal, 2016, 28(9): 1137-1144.

[7] Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions[J]. J Dent Res, 2013, 92(10): 860-867.

[8] Poblenz AT, Jacoby JJ, Singh S, et al. Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides[J]. Biochem Biophys Res Commun, 2007, 359(3): 510-515.

[9] Abdelmagid SM, Sondag GR, Moussa FM, et al. Mutation in osteoactivin promotes receptor activator of NF Kappa B ligand (RANKL)-mediated osteoclast differentiation and survival but inhibits osteoclast function[J]. J Biol Chem, 2015, 290(33): 20128-20146.

[10] Basak S, Behar M, Hoffmann A. Lessons from mathematically modeling the NF-Kappa B pathway[J]. Immunol Rev, 2012, 246(1): 221-238.

[11] Ihn HJ, Lee D, Lee T, et al. The 1, 2, 3-triazole derivative KP-A021 suppresses osteoclast differentiation and function by inhibiting RANKL-mediated MEK-ERK signaling pathway[J]. Exp Biol Med, 2015, 240(12): 1690-1697.

[12] Amano S, Chang YT, Fukui Y. ERK5 activation is essential for osteoclast differentiation[J]. PLoS One, 2015, 10(4): e0125054.

[13] Lee K, Chung YH, Ahn H, et al. Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation[J]. Int J Biol Sci, 2016, 12(2): 235-245.

[14] Siddiqi MH, Siddiqi MZ, Kang S, et al. Inhibition of osteoclast differentiation by ginsenoside Rg3 in RAW264.7 cells via RANKL, JNK and P38 MAPK pathways through a modulation of cathepsin K: an in silico and in vitro study[J]. Phytother Res, 2015, 29(9): 1286-1294.

[15] Choi SW, Park KI, Yeon JT, et al. Anti-osteoclastogenic activity of matairesinol via suppression of P38/ERK-NFATc1 signaling axis[J]. BMC Complem Altern M, 2014, 14: 35.

[16] Sen B, Styner M, Xie Z, et al. Mechanical loading regulates NFATc1 andβ-catenin signaling through a GSK3β control node[J]. J Biol Chem, 2009, 284(50): 34607-34617.

[17] Shi XD, Miller JS, Harper LJ, et al. Reactivation of cocaine reward memory engages the Akt/GSK3/MTOR signaling pathway and can be disrupted by GSK3 inhibition[J]. Psychopharmacology, 2014, 231(16): 3109-3118.

[18] Nagy V, Penninger JM. The RANKL-RANK story[J]. Gerontology, 2015, 61(5): 534-542.

[19] Liu W, Zhang XL. Receptor activator of nuclear factor-Kappa B ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues[J]. Mol Med Rep, 2015, 11(5): 3212-3218.

[20] An J, Hao D, Zhang Q, et al. Natural products for treatment of bone erosive diseases: the effects and mechanisms on inhibiting osteoclastogenesis and bone resorption[J]. Int Immunopharmacol, 2016, 36: 118-131.

[21] Xie BP, Shi LY, Li JP, et al. Oleanolic acid inhibits RANKL-induced osteoclastogenesisvia ER Alpha/MiR-503/RANK signaling pathway in RAW264.7 cells[J]. Biomed Pharmacother, 2019, 117: 109045.

[22] Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China[S]. Science and Technology Press of Shanghai, 2020: 39.

[23] Huang YL, Wang SS, Liu L, et al. Review of traditional uses, botany, chemistry, pharmacology, pharmacokinetics, and toxicology of Radix Cyathulae[J]. Chin Med, 2019, 14(1): 17.

[24] Wang Y, Zhou GJ, Yan ZX, et al. Estrogen effect of Cyathnla capitata Moq. in ovariectomized rats in vivo and its impact onlipid metabolism[J]. Mat Child Health Care China, 2015, 30(29): 5063-6.

[25] Wang Y, Zhou GJ, Yan ZX, et al. The protective effect of Cyathula officinalis Kuan on bone in ovariectomized rats[J]. Chin J Osteoporos, 2015, 21(8): 918-921.

[26] Wang YY, Zhang XQ, Yuan FF, et al. Research on the anti-inflammatory and immunodulatory activity of Cyathulae Radix and Achyranthis Bidentatae Radix polysaccharides[J]. J Jining Med Univ, 2018, 41(2): 132-134.

[27] Ji QL, Kong XD, Qi SH, et al. The experimental study of cyasterone on the treatment of osteoporosis through the bidirectional effect of inhibiting osteoclast differetiation and promoting osteoblast differentiation[J]. J Kunming Med Univ, 2018, 39(5): 21-28.

[28] Xie JC, Zhao Y, Huang LH, et al. Cupatosterone inhibits osteoclastic differentiation through estrogen-like effects[J]. Central South Pharm, 2022, 20(9): 2046-2051.

[29] Yan WJ, Zhong YY, Wang H, et al. Quantitative analysis of triterpenoid saponins in Cyathula officinalis by HPLC-ELSD[J]. Pharm Clin Res, 2014, 22(4): 336-338.

[30] Feng HB, Du XG, Liu J, et al. Novel polysaccharide from Radix Cyathulae officinalis Kuan can improve immune response to ovalbumin in mice[J]. Int J Biol Macromol, 2014, 65: 121-128.

[31] Li M, Hao L, Li L, et al. Cinnamtannin B-1 prevents ovariectomy-induced osteoporosis via attenuating osteoclastogenesis and ROS generation[J]. Front Pharmacol, 2020, 11: 1023-1036.

[32] Li J, Liang J, Wu L, et al. CYT387, a JAK-specific inhibitor impedes osteoclast activity and oophorectomy-induced osteoporosis[J]. Front pharmacol, 2022, 13: 829862-8299880.

[33] Liu S, Zhou H, Liu H, et al. Fluorine-contained hydroxyapatite suppresses bone resorption through inhibiting osteoclasts differentiation and function in vitro and in vivo[J]. Cell Proliferat, 2019, 52(3): e12613-12624.

[34] Tzeng HE, Huang PH, Tsai CH, et al. Isosteviol derivative inhibits osteoclast differentiation and ameliorates ovariectomy-induced osteoporosis[J]. Sci Rep, 2018, 8(1): 11190-11212.

[35] He JB, Chen MH, Lin DK. New insights into the tonifying kidney-yin herbs and formulas for the treatment of osteoporosis[J]. Arch Osteoporos, 2017, 12(1): 1-14.

[36] He J, Li X, Wang Z, et al. Therapeutic anabolic and anticatabolic benefits of natural Chinese medicines for the treatment of osteoporosis[J]. Front Pharmacol, 2019, 10: 1344.

[37] Wang T, Liu Q, Tjhioe W, et al. Therapeutic potential and outlook of alternative medicine for osteoporosis[J]. Curr Drug Targets, 2017, 18(9): 1051-1068.

[38] Suvarna V, Sarkar M, Chaubey P, et al. Bone health and natural products-an insight[J]. Front Pharmacol, 2018, 9: 981.

[39] Meng JH, Zhang WK, Wang C, et al. Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity[J]. Biochem Pharmacol, 2020, 171: 113715.

[40] Stemig M, Astelford K, Emery A, et al. Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF[J]. PLoS One, 2015, 10(4): e0123843.

[41] Swarnkar G, Chen TH, Arra M, et al. NUMBL interacts with TAK1, TRAF6 and NEMO to negatively regulate NF-κB signaling during osteoclastogenesis[J]. Sci Rep, 2017, 7(1): 12600-12610.

[42] Hamid A, Song J, Thakur N, et al. TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α[J]. Sci Signal, 2017, 10(486): 1-15.

[43] Abdallah BM, Stilgren LS, Nissen N, et al. Increased RANKL/OPG MRNA ratio in iliac bone biopsies from women with hip fractures[J]. Calcif Tissue Int, 2005, 76: 90-97.

Funding

National Natural Science Foundation of China(81273816)

National Natural Science Foundation of China(81774379)

National Natural Science Foundation of China(81370974)

Natural Science Foundation of Hunan Province, China(2017JJ2338)

Natural Science Foundation of Hunan Province, China(2020JJ4860)

Fundamental Research Funds for the Central Universities of Central South University(502211706)

Fund for the Key Laboratory of Hunan Province, China(2017TP1004)